StockData

Rocket Pharmaceuticals vs Soligenix

RCKT and SNGX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How RCKT and SNGX compare

Rocket Pharmaceuticals is the larger company, worth 38 times as much as Soligenix ($232M against $6.1M).

Soligenix scores higher on the StockData Score (6 against 3 for Rocket Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricRCKTSNGX
Size and price
Market cap$232M$6.1M
Share price$2.11$0.281
Change, 1 year−30.8%−79.5%
Change, 5 years−91.1%−99.9%
Beta (5Y)2.322.38
Employees20214
StockData Score
Total score36 (better)
Valuation score11
Growth score00
Performance score1 (better)0
Health score15 (better)
Dividend score00
Valuation
P/B0.6× (better)0.9×
FCF yield−73.6%–
Profitability
Return on equity−4.8% (better)−242%
Return on invested capital−180%–
Financial health
Debt / equity–0.00
Interest coverage−101.3×–
Current ratio9.24 (better)2.77
Altman Z-score−2.72 (better)−35.09
Piotroski F-score13 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions90.9%4.3%
Held by insiders22.3%0.69%
Insider net buying, 12 months−$934K–
Short interest, % of float19.0%0.31%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.